Skip to main content
. Author manuscript; available in PMC: 2015 Nov 6.
Published in final edited form as: Mol Cancer Res. 2014 Apr 25;12(7):979–986. doi: 10.1158/1541-7786.MCR-14-0158-T

Figure 2. Thyroid cancer development in mice wild-type, heterozygous or homozygous for Pik3caLat.

Figure 2

A: Kaplan-Meier survival curves comparing tamoxifen treated: 1. Thyro::CreER; BRafCA/+, Thyro::CreER; 2. Thyro::CreER; BRafCA/+; Pik3caLat/+ or; 3. Thyro::CreER; BRafCA/+; Pik3caLat/Lat mice after tumor initiation (**: P≤0.01; Log-Rank Test).

B: Tumor burden measured by ultrasonography (*P≤0.05; **: P≤0.01; t-Test).

C: Immunofluorescence staining for expression of TTF-1, E-Cadherin, Vimentin, Ki67 and Cytokeratin 19 in a histological section of thyroid from Thyro::CreER; BRafCA/+; Pik3caLat-HR/+ focusing on areas of papillary (PTC) or anaplastic thyroid carcinoma (ATC area) as indicated. Nuclear DNA was stained blue with DAPI.